Middle East and Africa Drug Delivery Market, By Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Middle East and Africa Drug Delivery Market Analysis and Size
The growth of drug delivery market has increased with growing acceptance of self-administering drugs and awareness about diagnosis and treatment in developed and developing countries. The domestic general government health expenditure by the African government in 2018 was surged by 70.5%. Furthermore, Saudi Arabia's elderly population aged 60 years and above will reach upto 25% of the country’s total population by 2050. This factor enhanced the market growth. Additionally, the increasing incidence of cardiovascular diseases has become a cause of major public health concern.
Data Bridge Market Research analyses a growth rate in the drug delivery market in the forecast period 2023-2030. The expected CAGR of drug delivery market is around 8.8% in the mentioned forecast period. The market is valued at USD 23.8 million in 2022, and it would grow upto USD 46.7 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Middle East and Africa Drug Delivery Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
|
|
Market Players Covered
|
Nemera (France), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), 3M (U.S.), Bayer AG (Germany), Takeda Pharmaceutical Company Limited (Japan)
|
|
Market Opportunities
|
|
Market Definition
Drug delivery is the process of introducing a therapeutic effect in the body of human by administering a drug at a specific targeted site. The safety and efficacy of drug can be improved by controlling the rate, time and release of drug in the body. There can be several ways of delivering drugs such as oral, pulmonary, nasal, injectable, and others. The drug delivery systems are advanced by studying and developing the properties of nanoparticles, which have made the drug delivery process more efficient and time-saving.
Middle East and Africa Drug Delivery Market Dynamics
Drivers
- Increasing Rates of Elderly Population
As per an article published in 2018, Saudi Arabia's elderly population aged 60 years and above will rise upto 25% of the country’s total population by 2050. Furthermore, the number of people aged 80 years and above is anticipated to reach 1.6 million, accounting for $4% of the total population in the same time frame. The healthcare spending in the country is expected to increase considerably in the upcoming years because of the rise in the aged population. Thus, this factor boost the market growth.
- Rising Cases of Cardiovascular Diseases
The growing occurrence of cardiovascular diseases (CVDs) has become a major public health concern. CVDs are primarily responsible for approximately 46% of the total mortality rate in the country. Injectable drug delivery technology has developed as a source of relief for the elderly and CVD patients since they help provide a better quality of life to them. This factor is boosting the growth of the KSA injectable drug delivery market during the forecast period 2023-2029. Thus, this factor increases the market growth.
Opportunities
- Increasing Preference Towards Feasible Routes of Administration
One of the developing trends in the topical drug delivery market is the delivery of biologics through the transdermal route. The wide use of transdermal delivery of big molecules provides significant patient benefits such as painless medication delivery and cost-effective treatment. This factor is expected to increase the growth of the market. Additionally, the preference towards administering drugs through the skin to control or extend drug delivery and using this process as a substitute to the oral route are also projected to boost market growth.
- Increasing Product Developments
Various product developments are started by numerous companies worlwide which are also increasing the growth of market. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. in February 2020 told about submitting a supplemental Biologics License Application (sBLA) to the U.S. FDA of DARZALEX combined with Kyprolis and dexamethasone which is used for the treatment of relapsed or refractory multiple myeloma. This as a result, increases the demand for the market.
Restraints/Challenges
- Increased Expenditure of Treatment
The high expenditure related with the drug delivery and the huge cost required to conduct the assays hinder the market growth. The increased cost associated with the manufacturing, supply and drug delivery is often not possible for the developing and underdeveloped countries, cause the under treatment of numerous patients. This impedes the market growth.
This drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug delivery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2020, Bayer AG completed the submission of application for the U.S. approval of nifurtimox, which is a drug for treating pediatric patients with Chagas disease. This will fix the condition of children suffering from this disease and also benefit the company as it is a novel formulation for children and revenue generation will be increased for the organization.
- In 2019, F. Hoffmann-La Roche Ltd completed the acquisition of Spark Therapeutics, Inc. Spark is an organization dedicated to investigational gene therapy. This will open several opportunities for Roche and also will lead to more revenues.
Middle East and Africa Drug Delivery Market Scope
The drug delivery market is segmented on the basis of product type, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Oral Drug Delivery
- Pulmonary Drug Delivery
- Injectable Drug Delivery
- Opthalmic Drug Delivery
- Nasal Drug Delivery
- Topical Drug Delivery
- Implantable Drug Delivery
- Transmucosal Drug Delivery
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Drug Delivery Market Regional Analysis/Insights
The drug delivery market is analyzed and market size insights and trends are provided by product type, end user, and distribution channel as referenced above.
The major countries covered in the drug delivery market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Middle East leads the market because of the increased adoption rate of numerous new technological advancements in the drug delivery. Also, the surge in elderly population and the rise in disposable income of the people within the region increases the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Drug Delivery Market Share Analysis
The drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to drug delivery market
Key players operating in the drug delivery market include:
- Nemera (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- 3M (U.S.)
- Bayer AG (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
SKU-